Veru (NASDAQ:VERU) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Veru (NASDAQ:VERU) from a sell rating to a strong sell rating in a report issued on Sunday,Wall Street Zen reports.

A number of other brokerages have also weighed in on VERU. Oppenheimer restated an “outperform” rating on shares of Veru in a report on Wednesday, October 14th. Weiss Ratings cut shares of Veru from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. Finally, Westpark Capital assumed coverage on shares of Veru in a report on Tuesday, October 6th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.50.

Veru Trading Down 3.2%

VERU stock opened at $2.12 on Friday. Veru has a 12-month low of $2.04 and a 12-month high of $7.33. The business’s 50-day moving average is $2.39 and its 200 day moving average is $2.48.

Veru (NASDAQ:VERU) last announced its earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. Research analysts expect that Veru will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Veru

Large investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new position in Veru in the 2nd quarter valued at approximately $328,000. Renaissance Technologies LLC purchased a new position in Veru in the first quarter valued at $153,000. Finally, Royal Bank of Canada grew its stake in Veru by 69.3% during the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after purchasing an additional 5,008 shares in the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc. is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function. Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.